Friday 26 April 2024
World's first jab to stop skin cancer being tested in UK patients
Experts say the treatment has huge potential and is "one of the most exciting developments in modern cancer therapy".
https://news.sky.com/story/uk-patients-test-gamechanger-bespoke-mrna-jab-for-melanoma-13123074

Beklager, det er de nok ikke.
SkyNews linken ble hentet fra denne artikkelen hvor blant andre Nykode nevnes: https://www.msn.com/nb-no/nyheter/norge/tester-historisk-kreftspr%C3%B8yte-kan-bli-livreddende/ar-AA1nLOGo

Teknologien er vel omtrent den samme, mRNA.

https://www.nettavisen.no/nyheter/tester-historisk-kreftsproyte-kan-bli-livreddende/s/5-95-1788173

Les denne. Nykode har også Et forsøk gående .

Pentagon

Q1 rapport i dag: https://newsweb.oslobors.no/message/618503

OUTLOOK FOR THE NEXT 12 MONTHS

Dose level recommendation for the VB-C-03 trial determining the biological optimal dose of VB10.16 in combination
with a fixed dose of pembrolizumab in H2 2024.

Finalization of enrolment for Part 1 of the VB-C-04 trial (VB10.16) in Q4 2024.

Update on Nykode’s APC targeted vaccine technology delivered by mRNA in Q2 2024.

Update on Nykode’s autoimmune disease program in Q2 2024.

Update on preclinical oncology vaccine program aimed at preventing and treating colorectal cancer (NYK011) in H2
2024.

Presentation of detailed clinical data from the updated analysis of the VB-C-02 trial (VB10.16) in advanced cervical
cancer in a future scientific publication or at a forthcoming conference.

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer

Oslo, Norway, May 14, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has expanded its collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to include a clinical trial collaboration and supply agreement for a phase 2 trial evaluating Nykode’s wholly-owned lead candidate, VB10.16, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). This study will enroll HPV16-positive high-risk patients with locally advanced cervical cancer undergoing chemoradiotherapy.
https://newsweb.oslobors.no/message/618520

Reprise: https://medwatch.no/nyheter/legemidler_biotek/article17099636.ece

Ikke så lett å forstå alt dette bio-teknologi greiene. At Merck utvider samarbeidet med Nykode derimot er stykre. Merck forstår bio-teknologi.

Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy

Oslo, Norway, June 11, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format.
Les resten: https://newsweb.oslobors.no/message/621130

Oslo, Norway, June 20, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced advancements in its inverse vaccine platform at the annual Federation of Clinical Immunology Societies (FOCIS) meeting in San Francisco. https://newsweb.oslobors.no/message/621941

Satser på fet reprising om litt👍